ALRN
Aileron Therapeutics Inc

5,632
Loading...
Loading...
News
all
press releases
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Aileron Therapeutics Announces Rebranding to Rein Therapeutics Aileron Therapeutics Announces Rebranding to Rein Therapeutics PR Newswire AUSTIN, Texas, Jan. 10, 2025 Rebrand to Rein Therapeutics is...
PR Newswire·8mo ago
News Placeholder
More News
News Placeholder
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR...
PR Newswire·10mo ago
News Placeholder
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) Aileron Therapeutics Announces Positive Topline Data...
PR Newswire·10mo ago
News Placeholder
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma Aileron Therapeutics and Advancium Health Network Announce...
PR Newswire·10mo ago
News Placeholder
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on...
PR Newswire·11mo ago
News Placeholder
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) Aileron Therapeutics Completes Enrollment in...
PR Newswire·1y ago
News Placeholder
Aileron Therapeutics to Present at the 8th Annual IPF Summit
Aileron Therapeutics to Present at the 8th Annual IPF Summit Aileron Therapeutics to Present at the 8th Annual IPF Summit PR Newswire AUSTIN, Texas, Aug. 19, 2024 AUSTIN, Texas, Aug. 19, 2024...
PR Newswire·1y ago
News Placeholder
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights PR Newswire...
PR Newswire·1y ago
News Placeholder
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire AUSTIN...
PR Newswire·1y ago
News Placeholder
Aileron Therapeutics to be Included in the Russell Microcap Index
Aileron Therapeutics to be Included in the Russell Microcap Index Aileron Therapeutics to be Included in the Russell Microcap Index PR Newswire AUSTIN, Texas, July 1, 2024 AUSTIN, Texas, July 1, 2024...
PR Newswire·1y ago

Latest ALRN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.